The manufacturing of medicinal products is for us not only a matter of implementing a certain technological process, but a human mission based on high standards of quality, safety and efficacy of medications
Sopharma’s (3JR BU) smoking cessation drug with positive preliminary clinical trial data in the US, the Company’s American partner Achieve Life Sciences (NASDAQ: ACHV) announced in a statement.
Sopharma AD notifies that on 29 December 2017 the Company bought 1186 own shares representing 0.00088% of the share capital of the Company, at a total value of 5080.82 BGN on the Bulgarian Stock Exchange, the average price per share was 4.28 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 8 904 000, representing 6.61% of the share capital of the Company.
Sopharma AD notifies that for January 2018 the Company recorded an increase of sales revenues of 3% compared to the same month of 2017, including 5% increase of export sales and same level of domestic sales.
Sopharma AD ended its most successful financial year after the crisis. 2017 ended with 12.5% revenue growth reaching 205.3 million BGN, 44.8% increase in operating profit, 30.7% EBITDA growth and almost 10% growth in net profit.
During this successful year, the company took two important investment decisions, namely to start the construction of:
1. An extraction plant in Kazanlak, which will allow more effective and modern production of all phyto products and
Sopharma AD received a notification for the sale of 250 000 shares, representing 0.19% of its capital, by CUPF Allianz Bulgaria. After the transaction the share of CUPF Allianz Bulgaria in the capital of Sopharma AD reached 4.99%.
The date of the registration of the transaction with the Central Depository is 24 January 2018.